Ramesh Subbiah Email & Phone Number

United States

• Serving as a scientific expert accountable for educating, training, and troubleshooting the cell therapy workflow for the engineers and scientists of biopharmaceutical industries. • Responsible for special projects, client collaboration, and scientific novelty and value analysis of customer training.• Established relationships with lead scientists and engineers of 15 biopharma companies in the Pacific Northwest and Bay area; training industry employees in the use of cutting edge instruments including Rotea (PBMC isolation/wash/concentrate), Xenon (gene editing), and Dynacellect (magnetic associated cell separation) and security, audit, and electronic signature (SAE) Administrator Console Software for the establishment of cell therapy workflow platforms at GMP facilities.• Collaborates with the team of product development, technology transfer, MSAT and GMP manufacturing engineers. Repeatedly receives excellent customer reviews.• Leveraging competitive analysis results to improve instrument functionality and cell therapy workflow efficiency. • Helping biopharma clients troubleshoot challenges faced during the transition from PD to GMP manufacturing and CFR part 11 compliance that is an essential component of FDA regulation.

Portland, Oregon, United States

• Gained as a Senior Postdoc, Bone Subgroup Leader and Cell Therapy Product Development Project Leader. • Responsible for design and manage project plans comprising technical, regulatory, and business milestones. • Developed a human vascularized bone-on-a-chip system for investigating hematopoiesis and breast/prostate cancer metastasis to bone; lead two NIH funded projects; developed two IACUC protocols, in vivo models, and SOP’s.• Overseen project performance in process optimization and commercial feasibility validation, product formulation lock-in, and designing of pre-GLP studies.• Managed 10+ scientists working on cancer therapy and bone regeneration projects with a budget of $3.5 million funded by federal and public agencies such as NIH R01 & R21, Osteoscience Foundation, and School of Dentistry seed grant.• Contributed to internal and external science communication initiatives, as well as partnerships for commercial research and development initiatives. Invited to present at over 13 conferences and lectures over two years. • Contributed to the development of a dual-acting anti-cancer therapeutic that inhibits cancer cell motility and osteoclast-mediated bone destruction, in collaboration with the OHSU Knight Cancer Institute.• Conducted three (3) preclinical studies resulting in high-impact publications • Instructed two post-graduate level courses for dental and biomedical students on modern drug delivery systems, advanced biomaterials, and regenerative medicine; mentored 5 PG students.• Conducted customer discovery and go-to-market planning for a novel biomaterial, RegendoGEL (a Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center for product commercialization).• Helped establish the newly funded OHSU Biofabrication Hub, a center located within the Knight Cancer Institute that is devoted to developing lab grown organs for transplant and clinical studies.

Greater Atlanta Area

• Gained as Postdoc and co -investigator at Guldberg’s musculoskeletal regenerative medicine laboratory. • Leadership and management of a multi-disciplinary laboratory with limited supervision, and direct responsibility for six PhD candidates and five undergraduate researchers. Responsible for management of funding and chemical inventory, as well as three IACUC protocols, including compliance with required regulatory standards, data collection, analysis, and presentation.• Co-PI for the “Spatiotemporal Regenerative Strategies to Restore Function to Severely Injured Extremities” subcontract from the Armed Forces Institute for Regenerative Medicine (AFIRM).• Conducted preclinical studies investigating the regenerative potential of multiple therapeutic proteins and immunoengineering on vascularized musculoskeletal tissue regeneration, resulting in 3 publications.• Invited lecturer at the Indonesian Medical Education and Research Institute (IMERI) of Universitas Indonesia.• Served on the scientific advisory board for FlexSpark Inc., a Georgia Tech venture-backed startup developing a mechanical prophylactic device to prevent deep vein thrombosis and pulmonary embolism.

Seongbuk-Gu, Seoul, Korea

• Earned Ph.D. in Biomedical Engineering for the development of controlled delivery system for therapeutic proteins, engineered biomaterials for stem cell differentiation to heal bone defect. • Presented data on research projects and primary literature in weekly meetings, conferences, and advisory boards, resulting in receiving two travel awards for presentation at international conferences.• Mentored undergraduate and postgraduate students .• Pioneered a cross-functional collaboration with external experts (EEs) while leveraging expertise in nanomedicine and pharmaceutical formulation served as the foundation for further studies. • Maintained strong scientific knowledge of tissue engineering and regenerative medicine through critical evaluation of published studies, attendance at scientific congresses, and investigator meetings.• Led a tissue engineering and regenerative medicine project that focused on therapeutic (cells, proteins, small molecules) delivery systems using core-shell microparticles, chitosan, PLGA, and Lipid nanoparticles, cell-derived extracellular matrix for stem cell differentiation application.• Atomic force microscopy (AFM) with nanoindentation for the analysis of biomechanical and biophysical properties of biological samples at standard culture condition.• Successfully managed a demanding workload, balancing academic excellence while dedicating 40+ hours weekly to lab responsibilities, showcasing exceptional time management and multitasking abilities.

Seongbuk-Gu, Seoul, Korea

• Led a nanomaterial project that focussed on the synthesis and functionalization of graphene oxide and quantum dots (InP/ZnS core-shell QDs) and it's nano and bio applications

Seongnam, Gyeonggi, South Korea

Led a nano-bio tech project that focussed on the synthesis of antibacterial and pro-regenerative composite materials using carbon nanotubes, silver nanoparticles, PVA polymer, and DNA for wound healing application.

Bangalore, India

• Responsible for building a network of Key Opinion Leaders (KOLs), including intensivists, neurologists, oncologists, pulmonologists, nephrologists, cardiologists, and related specialty surgeons. • Managed sales, and inventory of multiple therapeutics including: Augmentin, Arixtra, Ceftum, Flixonase, Fortum, Seretide, Timentin, Zovirax, and Fraxiparine. Participated in and managed multiple product launches.• Fostered productive relationships with a network of over 200 PCPs and KOLs within a 3000-square-mile territory encompassing six cities with over 30 major hospitals.• Received the top performance award three years in a row (2006-2008) for exceeding sales targets over 110% each year.• Earned the best brand promoter award for Augmentin in 2006 and 2007.• Developed and delivered training programs for pulmonary care products to 250 healthcare professionals in a clinical care setting.• Responsible for the territory-wide product launch of Arixtra, a blood thinner and prophylactic to prevent deep vein thrombosis and pulmonary embolism.

Doctor Of Philosophy (Phd) - Phd, Biomedical Engineering, Tissue Engineering And Regenerative Medicine, A

Dissertation title: Engineered Extracellular Microenvironments for Cell Differentiation and Tissue Regeneration Application * Received.

Bachelor Of Pharmacy (Bpharm), Pharmacy, Pharmaceutical Sciences, And Administration, A

Dissertation Title: Synthesis, Characterization and Antimicrobial studies of some 1, 2, 4-Triazole derivatives

Master'S Degree - Biomedical Engineering, Wound Healing And Nanomedicine, A

Dissertation Title: Fabrication of Bio-Nanofilm for Biomedical Applications * Received Post-Graduate Scholarship from the Ministry.